spa-s-843 and Aspergillosis

spa-s-843 has been researched along with Aspergillosis* in 2 studies

Other Studies

2 other study(ies) available for spa-s-843 and Aspergillosis

Article	Year
Efficacy of SPK-843, a novel polyene antifungal, in comparison with amphotericin B, liposomal amphotericin B, and micafungin against murine pulmonary aspergillosis. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:5 SPK-843, a new polyene antifungal, exhibited dose-dependent efficacy on murine pulmonary aspergillosis models. SPK-843 doses of higher than 1.0 mg/kg of body weight exhibited no renal toxicities and a tendency toward better survival prolongation than the estimated maximum tolerated doses of amphotericin B (Fungizone) (1.0 mg/kg) and liposomal amphotericin B (AmBisome) (8.0 mg/kg). Topics: Amphotericin B; Animals; Antifungal Agents; Aspergillosis; Aspergillus flavus; Disease Models, Animal; Dose-Response Relationship, Drug; Echinocandins; Lipopeptides; Lipoproteins; Lung Diseases, Fungal; Male; Micafungin; Mice; Polyenes; Treatment Outcome	2008
In vitro activity of a new polyene SPK-843 against Candida spp, Cryptococcus neoformans and Aspergillus spp clinical isolates. Journal of chemotherapy (Florence, Italy), 2003, Volume: 15, Issue:3 Topics: Antifungal Agents; Aspergillosis; Aspergillus; Candida; Candidiasis; Cryptococcosis; Cryptococcus neoformans; Drug Resistance, Multiple, Fungal; Humans; Italy; Microbial Sensitivity Tests; Polyenes; Sensitivity and Specificity	2003

Article

Year

Efficacy of SPK-843, a novel polyene antifungal, in comparison with amphotericin B, liposomal amphotericin B, and micafungin against murine pulmonary aspergillosis.

Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:5

SPK-843, a new polyene antifungal, exhibited dose-dependent efficacy on murine pulmonary aspergillosis models. SPK-843 doses of higher than 1.0 mg/kg of body weight exhibited no renal toxicities and a tendency toward better survival prolongation than the estimated maximum tolerated doses of amphotericin B (Fungizone) (1.0 mg/kg) and liposomal amphotericin B (AmBisome) (8.0 mg/kg).

Topics: Amphotericin B; Animals; Antifungal Agents; Aspergillosis; Aspergillus flavus; Disease Models, Animal; Dose-Response Relationship, Drug; Echinocandins; Lipopeptides; Lipoproteins; Lung Diseases, Fungal; Male; Micafungin; Mice; Polyenes; Treatment Outcome

2008

In vitro activity of a new polyene SPK-843 against Candida spp, Cryptococcus neoformans and Aspergillus spp clinical isolates.

Journal of chemotherapy (Florence, Italy), 2003, Volume: 15, Issue:3

Topics: Antifungal Agents; Aspergillosis; Aspergillus; Candida; Candidiasis; Cryptococcosis; Cryptococcus neoformans; Drug Resistance, Multiple, Fungal; Humans; Italy; Microbial Sensitivity Tests; Polyenes; Sensitivity and Specificity

2003